Trial Search Results

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorothymidine, which is taken up by cells that are actively proliferating or dividing such as cancer cells. We hope to learn whether this tracer is superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma (DLBCL).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):


  • Diagnostic Test: FLT-PET/CT
  • Diagnostic Test: FDG-PET/CT
  • Drug: FLT




Inclusion Criteria:

   - All patients must have a histologic or cytological diagnosis of de novo DLBCL and be
   scheduled to receive first line chemotherapy with R-CHOP given every 21 days
   (R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.

   - Patients must be >=18 years of age, but there will be no discrimination based on
   gender, race, creed, or ethnic background.

   - Patients must have an ECOG performance status of 0-2.

   - Patients must sign an informed consent, and be mentally responsible.

Exclusion Criteria:

   - Subjects with significant concurrent medical complications that in the judgment of the
   Principal Investigator(s) could affect the patient's ability to complete the planned
   trial, including the multiple imaging studies.

   - Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second
   cancers other than basal cell carcinoma.

   - Patients planned to be treated with R-CHOP-14 (i.e., R-CHOP given every 14 days) will
   be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard

   - Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT,
   radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.

   - Pregnant women will be excluded.

   - Women of child-bearing potential and men must agree to use adequate contraception
   (hormonal or barrier method of birth control; abstinence) after study entry and for
   the duration of study participation. The effects of FLT on the developing human fetus
   are unknown. Should a woman become pregnant or suspect she is pregnant while
   participating in this study, she should inform her treating physician immediately. A
   screening urine human chorionic gonadtropin (hCG) (pregnancy test) will be
   administered in Nuclear Medicine to women of childbearing potential before each FLT
   scan and pregnant women will be stopped from participating further in this study.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Krithika Rupnarayan